61442 Federal Register / Vol. 70, No. 204 / Monday, October 24, 2005 / Notices 

information collected; and (4) ways to 

minimize the burden of the collection of 

information on applicants and housing 

associates, including through the use of 

automated collection techniques or 

other forms of information technology. 

Comments may be submitted to OMB in 

writing at the address listed above. 

Dated: October 17, 2005. 

By the Federal Housing Finance Board. 

John P. Kennedy, 

General Counsel. 

[FR Doc. 05–21148 Filed 10–21–05; 8:45 am] 

BILLING CODE 6725–01–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisition of Shares of Bank or Bank 

Holding Companies 

The notificants listed below have 

applied under the Change in Bank 

Control Act (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire a bank or bank 

holding company. The factors that are 

considered in acting on the notices are 

set forth in paragraph 7 of the Act (12 

U.S.C. 1817(j)(7)). 

The notices are available for 

immediate inspection at the Federal 

Reserve Bank indicated. The notices 

also will be available for inspection at 

the office of the Board of Governors. 

Interested persons may express their 

views in writing to the Reserve Bank 

indicated for that notice or to the offices 

of the Board of Governors. Comments 

must be received not later than 

November 8, 2005. 

A. Federal Reserve Bank of Kansas 

City (Donna J. Ward, Assistant Vice 

President) 925 Grand Avenue, Kansas 

City, Missouri 64198-0001: 

1. Alan R. Fairman, DuBois, 

Pennsylvania, Beverly A. Fairman, 

Ronald L. Fairman, and Ann W. 

Fairman, all of Punxsutawney, 

Pennsylvania, acting as a group in 

concert, to acquire control of New 

Mexico Banquest Corporation, parent of 

First National Bank of Santa Fe, both in 

Santa Fe, New Mexico. 

In connection with this application, 

Johnny P. Crowley, Glorieta, New 

Mexico, as trustee of the New Mexico 

Banquest Corporation Employee Stock 

Ownership Plan Trust, Santa Fe, New 

Mexico, to acquire control of New 

Mexico Banquest Corporation, parent of 

First National Bank of Santa Fe, both in 

Santa Fe, New Mexico. 

Board of Governors of the Federal Reserve 

System, October 19, 2005. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E5–5856 Filed 10–21–05; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The application also will be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Additional information on all bank 

holding companies may be obtained 

from the National Information Center 

website at http://www.ffiec.gov/nic/. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than November 18, 

2005. 

A. Federal Reserve Bank of Chicago 

(Patrick M. Wilder, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690-1414: 

1. CenterBank Financial, Inc., 

Northfield, Illinois; to become a bank 

holding company by acquiring 100 

percent of the voting shares of 

CenterBank and Trust, National 

Association (in organization), Deerfield, 

Illinois. 

Board of Governors of the Federal Reserve 

System, October 19, 2005. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E5–5855 Filed 10–21–05; 8:45 am] 

BILLING CODE 6210–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Toxicology Program (NTP); 

Liaison and Scientific Review Office 

(LSRO); NTP High Throughput 

Screening Assays Workshop 

AGENCY: National Institute of 

Environmental Health Sciences 

(NIEHS), National Institutes of Health 

(NIH). 

ACTION: Workshop Announcement and 

Request for Public Comment. 

SUMMARY: The NTP has developed and 

refined a vision for toxicology in the 

21st century (‘‘NTP Vision’’) and a 

roadmap for implementing its vision 

(‘‘NTP Roadmap’’) to strategically place 

the program at the forefront of providing 

scientific data and its interpretation for 

use in public health decision-making 

(see NTP Web site http:// 

ntp.niehs.nih.gov select ‘‘NTP Vision 

and Roadmap’’). As part of the NTP 

Roadmap, the NTP will convene a series 

of workshops, including the High 

Throughput Screening Assays 

Workshop, to discuss test methods and 

approaches that will enhance the 

program’s ability to efficiently evaluate 

the large number of substances in our 

environment for which there is little or 

no information about their potential 

hazard for human health. This 

workshop is scheduled for December 

14–15, 2005, at the Hyatt Regency 

Crystal City, 2799 Jefferson Davis 

Highway, Arlington, VA and will focus 

on providing information about high 

throughput screening techniques and 

the potential utility of this technology 

for toxicology and the NTP. This 

meeting is open to the public and 

attendance is limited only by the space 

available. Individuals may register to 

attend the workshop on a first-come, 

first-served basis per the procedures 

outlined below. A copy of the agenda 

and any additional information about 

the workshop, including background 

materials and participants, will be 

posted on the NTP Web site when 

available (see NTP Web site http:// 

ntp.niehs.nih.gov select ‘‘Meetings and 

Workshops’’). 

DATES: The workshop will be held on 

December 14–15, 2005. The workshop 

will begin each day at 8:30 a.m. and end 

at approximately 5 p.m. on December 14 

Federal Register / Vol. 70, No. 204 / Monday, October 24, 2005 / Notices 61443 

and approximately 3 p.m. on December 

15. 

Comments: Written comments should 

be received by December 5, 2005, to 

allow time for adequate review before 

the workshop (see FOR FURTHER

INFORMATION CONTACT below). The 

deadline for registration to present oral 

comments at the meeting is December 8, 

2005. 

Registration: Individuals who plan to 

attend are encouraged to register online 

at the NTP Web site http:// 

ntp.niehs.nih.gov/ select ‘‘Meetings and 

Workshops’’ as soon as possible because 

seating is limited. Persons needing 

special assistance, such as sign language 

interpretation or other reasonable 

accommodation in order to attend, 

should contact 919–541–2475 voice, 

919–541–4644 TTY (text telephone), 

through the Federal TTY Relay System 

at 800–877–8339, or by e-mail to 

niehsoeeo@niehs.nih.gov. Requests 

should be made at least 7 days in 

advance of the event. 

ADDRESSES: The workshop will be held 

at the Hyatt Regency Crystal City, 2799 

Jefferson Davis Highway, Arlington, VA. 

FOR FURTHER INFORMATION CONTACT: 

Public comments and any other 

correspondence should be submitted to 

Dr. Barbara Shane (NTP Liaison and 

Scientific Review Office, NIEHS, P.O. 

Box 12233, MD A3–01, Research 

Triangle Park, NC 27709; telephone: 

919–541–4253, fax: 919–541–0295; or email: shane@niehs.nih.gov). 

SUPPLEMENTARY INFORMATION: 

Background 

The High Throughput Screening 

Assays Workshop will include plenary 

sessions as well as four simultaneous 

breakout group sessions for in-depth 

discussion. Each breakout group will 

address one of the following topics: (1) 

The selection of targets and assays for 

high throughput screening; (2) the 

conduct of studies including chemical 

selection, study design, and analytical 

methods; (3) data storage, analysis, and 

interpretation; and (4) the application of 

data from high throughput screening 

assays in regulatory decision-making. 

Following the workshop, the NTP will 

prepare a workshop report and present 

its proposed strategy to the NTP Board 

of Scientific Counselors for its 

consideration and input. 

Request for Comments 

Public input at this meeting is invited 

and time is set aside for the presentation 

of public comments during the plenary 

session on December 14. Each 

organization is allowed one speaker 

during the public comment period. At 

least 7 minutes will be allotted to each 

speaker, and if time permits, may be 

extended to 10 minutes. Registration for 

oral comments will also be available onsite, although time allowed for 

presentation by on-site registrants may 

be less than that for pre-registered 

speakers and will be determined by the 

number of persons who register at the 

meeting. 

Written statements can supplement 

and may expand the oral presentation. 

If registering on-site and reading from 

written text, please bring 40 copies of 

the statement for distribution and to 

supplement the record. Written 

comments received in response to this 

notice will be posted on the NTP Web 

site (http://ntp.niehs.nih.gov select 

‘‘Meetings and Workshops’’). Persons 

submitting written comments should 

include their name, affiliation, mailing 

address, phone, fax, e-mail, and 

sponsoring organization (if any) with 

the document. 

Dated: October 13, 2005. 

Samuel H. Wilson, 

Deputy Director, National Institute of 

Environmental Health Sciences. 

[FR Doc. 05–21130 Filed 10–21–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Scientific Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

and the Acting Assistant Secretary for 

Health have taken final action in the 

following case: 

Xiaowu Li, MD, PhD, The University 

of California at San Francisco: On 

September 16, 2005, the U.S. Public 

Health Service (PHS) entered into a 

Voluntary Exclusion Agreement with 

the University of California at San 

Francisco (UCSF) and Xiaowu Li, MD, 

PhD, former postdoctoral fellow at 

UCSF. Based on the UCSF report and 

additional analysis conducted by ORI in 

its oversight review, PHS found that Dr. 

Li engaged in scientific misconduct in 

reporting research supported by grants 

P01 DE13904, ‘‘Adhesion and 

proliferation in oral cancer 

progression,’’ R01 DE12856, ‘‘Oral 

melanoma alpha v beta 3 expression and 

metastasis,’’ and R01 DE011930, 

‘‘Regulatory function of fyn in oral SCC 

invasion,’’ all funded by the National 

Institute of Dental and Craniofacial 

Research (NIDCR), National Institutes of 

Health (NIH). 

Specifically, PHS found that Dr. Li 

falsified three images in Figure 5B of a 

paper, ‘‘Laminin-5 promotes cell 

motility by regulating the function of 

the integrin a6b1 in pancreatic cancer,’’

published online in Carcinogenesis 

Advance Access, reporting studies on 

the role of integrin a6b1 and laminin on 

the invasiveness of pancreatic cancer 

cells and their ability to metastasize. 

In all three images, mouse melanoma 

cells were falsely represented as being 

human pancreatic carcinoma cells; the 

cancer cells were falsely represented as 

having been plated on medium with 

laminin-1, whereas they were in fact 

plated on medium with vitronectin; and 

for two of the three images, the cancer 

cells were falsely represented as having 

been stained with anti-integrin b1, 

whereas they were actually stained with 

anti-integrin b3. 

The misconduct was significant 

because pancreatic cancer has a poor 

prognosis for patients, since it tends to 

invade other tissues and to metastasize 

early in its course. Knowledge of the 

factors that facilitate cancer cell 

invasion and metastasis, which was the 

focus of the questioned figure and 

paper, is crucial to attempts to develop 

better treatments for pancreatic and 

other cancers. Thus, the falsified figure 

could have misled other investigators in 

this important area of medical research. 

Dr. Li has entered into a Voluntary 

Exclusion Agreement (Agreement) in 

which he has voluntarily agreed, for a 

period of three (3) years, beginning on 

September 16, 2005: 

(1) To exclude himself from any 

contracting or subcontracting with any 

agency of the United States Government 

and from eligibility or involvement in 

nonprocurement programs of the United 

States Government referred to as 

‘‘covered transactions’’ as defined in the 

debarment regulations at 45 CFR Part 

76; and 

(2) To exclude himself from serving in 

any advisory capacity to PHS including 

but not limited to service on any PHS 

advisory committee, board, and/or peer 

review committee, or as consultant. 

FOR FURTHER INFORMATION CONTACT: 

Director, Division of Investigative 

Oversight, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (301) 443–5330. 

Chris B. Pascal, 

Director, Office of Research Integrity. 

[FR Doc. 05–21150 Filed 10–21–05; 8:45 am] 

BILLING CODE 4150–31–P